Skip to content
DataLookout
Menu

NCT06052956

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 3 words Show 4 more changesShow less
    • Enrollment increased: 120 → 150 participants
    • Interventions modified
    • Secondary endpoints: 3 to 1
    • Study description expanded, about 32 words
  2. Notable Primary and study completion pushed from Jun 30, 2031 to Jun 30, 2032 Show 4 more changesShow less
    • Start date: Jul 15, 2026 to Jul 15, 2027
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
  3. Notable Primary and study completion dates: Nov 15, 2030 to Jun 30, 2031
    • Start date: Dec 15, 2025 to Jul 15, 2026
    v7
  4. Minor Enrollment target: 90 to 120
    • Primary and study completion dates: Nov 2030 to Nov 15, 2030
    • Start date: Dec 2025 to Dec 15, 2025
    v6
  5. Notable Eligibility criteria expanded, about 12 words
    • Primary endpoint revised
    • Secondary endpoints revised (3)
    • Study description shortened, about 47 words
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Primary and study completion dates: Dec 2029 to Nov 2030
    • Start date: Jan 2025 to Dec 2025
    v4
  2. Notable Enrollment target: 60 to 90
    • Primary and study completion dates: Apr 2028 to Dec 2029
    • Start date: May 2024 to Jan 2025
    v3
  3. Minor Study title shortened, about 6 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to removal of the drainage catheter
Timeframe: Day 1 post-intervention until removal of drainage catheter

Secondary (1)

Mean Change in bacterial burden

Arms and interventions

MB-PDT at pre-defined dose plus standard of care abscess drainageExperimental

Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, and laser illumination at an optical power defined by their abscess size.

MB-PDT at patient-specific dose plus standard of care abscess drainageExperimental

Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, optical spectroscopy, and laser illumination. The optical power for laser illumination will be determined by their abscess morphology and the results of optical spectroscopy.

Sham control plus standard of care abscess drainageOther

Each subject in this arm will receive standard of care abscess drainage, inert blue blue dye, lipid emulsion, and fiber insertion without laser illumination.

Drugs: Methylene Blue, Lipid Emulsion, Inert blue dye

Devices: Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose)

Procedures: Standard of care abscess drainage

Sites

2 sites in 1 country